Asset
PELCITOCLAX
Ascentage Pharma Group International American Depository Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04001777 | phase1 | active_not_recruiting | 2019-07-04 | 2025-12-01 | Ascentage Pharma Group Inc. | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients |
| NCT04354727 | phase1_2 | withdrawn | 2020-12-15 | 2022-12-15 | Ascentage Pharma Group Inc. | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy |
| NCT03080311 | phase1 | completed | 2017-02-12 | 2020-06-22 | Ascentage Pharma Group Inc. | A Study of APG-1252 in Patients With SCLC or Other Solid Tumors |
| NCT05186012 | phase1_2 | unknown | 2022-06-14 | 2025-09-01 | Ascentage Pharma Group Inc. | APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma |
| NCT03387332 | phase1 | terminated | 2017-12-01 | 2020-11-09 | Ascentage Pharma Group Inc. | APG-1252 in Patients With SCLC or Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.